Aspirin for Evidence-Based Preeclampsia Prevention trial: influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia

American Journal of Obstetrics and Gynecology

Volumn 217, Issue 6, 2017, Pages 685.e1-685.e5

  Wright, David ^a   Poon, Liona C ^b,g   Rolnik, Daniel L ^b   Syngelaki, Argyro ^b   Delgado, Juan Luis ^h   Vojtassakova, Denisa ^b,c   de Alvarado, Mercedes ^b,d   Kapeti, Evgenia ^b,e   Rehal, Anoop ^b,f   Pazos, Andrea ⁱ   Carbone, Ilma Floriana ^k   Dutemeyer, Vivien ^l   Plasencia, Walter ^j   Papantoniou, Nikos ^m   Nicolaides, Kypros H ^b  

^a UNIVERSITY OF EXETER   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c MEDWAY MARITIME HOSPITAL   (United Kingdom)

^d HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

^e NORTH MIDDLESEX UNIVERSITY HOSPITAL   (United Kingdom)

^f SOUTHEND UNIVERSITY HOSPITAL   (United Kingdom)

^g CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^h HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

ⁱ HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^j Grupo Hospiten   (Spain)

^k FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^l BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

^m NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

more..

Author keywords

aspirin; Aspirin for Evidence Based Preeclampsia Prevention trial; compliance; first trimester screening; mean arterial blood pressure; placental growth factor; prediction; preeclampsia; pregnancy associated plasma protein A; pyramid of pregnancy care; treatment effect; uterine artery Doppler

Indexed keywords

ACETYLSALICYLIC ACID; PLACEBO; ANTITHROMBOCYTIC AGENT; PAPPA1 PROTEIN, HUMAN; PGF PROTEIN, HUMAN; PLACENTAL GROWTH FACTOR; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ADULT; AFRICAN CARIBBEAN; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EVIDENCE BASED PRACTICE; FEMALE; HUMAN; INCIDENCE; MATERNAL AGE; MEDICAL HISTORY; MEDICATION COMPLIANCE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PREECLAMPSIA; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SMOKING; SOUTH ASIAN; DIAGNOSTIC IMAGING; ETHNIC GROUP; EVIDENCE BASED MEDICINE; FIRST TRIMESTER PREGNANCY; METABOLISM; PREGNANCY; PREMATURITY; PULSATILE FLOW; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL MODEL; TREATMENT OUTCOME; UTERINE ARTERY; YOUNG ADULT;

ADULT; ASPIRIN; DOUBLE-BLIND METHOD; ETHNIC GROUPS; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; LOGISTIC MODELS; MATERNAL AGE; MEDICATION ADHERENCE; PLACENTA GROWTH FACTOR; PLATELET AGGREGATION INHIBITORS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PREMATURE BIRTH; PULSATILE FLOW; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; SMOKING; TREATMENT OUTCOME; UTERINE ARTERY; YOUNG ADULT;

EID: 85030626972     PISSN: 00029378     EISSN: 10976868     Source Type: Journal    
DOI: 10.1016/j.ajog.2017.08.110     Document Type: Article

References (23)

1. Meher, S., Duley, L., Hunter, K., Askie, L., Antiplatelet therapy before or after 16 weeks’ gestation for preventing preeclampsia: an individual participant data meta-analysis. Am J Obstet Gynecol 216 (2017), 121–128.
2. Roberge, S., Nicolaides, K., Demers, S., Hyett, J., Chaillet, N., Bujold, E., The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. Am J Obstet Gynecol 216 (2017), 110–120.e1-6.
3. Rolnik, D.L., Wright, D., Poon, L.C., et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med 77 (2017), 613–622.
4. Akolekar, R., Syngelaki, A., Poon, L., Wright, D., Nicolaides, K.H., Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther 33 (2013), 8–15.
5. Coronary Drug Project Research Group, Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. N Engl J Med 303 (1980), 1038–1041.
6. Manninen, V., Elo, M.O., Frick, M.H., et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 260 (1988), 641–651.
7. Cramer, J.A., Effect of partial compliance on cardiovascular medication effectiveness. Heart 88 (2002), 203–206.
8. Cramer, J.A., Benedict, A., Muszbek, N., Keskinaslan, A., Khan, Z.M., The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidemia: a review. Int J Clin Pract 62 (2008), 76–87.
9. Simpson, S.H., Eurich, D.T., Majumdar, S.R., et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ, 333, 2006, 15.
10. Shingler, S.L., Bennett, B.M., Cramer, J.A., Towse, A., Twelves, C., Lloyd, A.J., Treatment preference, adherence and outcomes in patients with cancer: literature review and development of a theoretical model. Curr Med Res Opin 30 (2014), 2329–2341.
11. Romero, R., Erez, O., Hüttemann, M., et al. Metformin, the aspirin of the 21st century: its role in gestational diabetes mellitus, prevention of preeclampsia and cancer, and the promotion of longevity. Am J Obstet Gynecol 217 (2017), 282–302.
12. Wright, D., Syngelaki, A., Akolekar, R., Poon, L.C., Nicolaides, K.H., Competing risks model in screening for preeclampsia by maternal characteristics and medical history. Am J Obstet Gynecol 213 (2015), 62.e1–62.e10.
13. Poon, L.C., Zymeri, N.A., Zamprakou, A., Syngelaki, A., Nicolaides, K.H., Protocol for measurement of mean arterial pressure at 11-13 weeks' gestation. Fetal Diagn Ther 31 (2012), 42–48.
14. Plasencia, W., Maiz, N., Bonino, S., Kaihura, C., Nicolaides, K.H., Uterine artery Doppler at 11+0 to 13+6 weeks in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol 30 (2007), 742–749.
15. Wright, A., Wright, D., Ispas, A., Poon, L.C., Nicolaides, K.H., Mean arterial pressure in the three trimesters of pregnancy: effects of maternal characteristics and medical history. Ultrasound Obstet Gynecol 45 (2015), 698–706.
16. Tayyar, A., Guerra, L., Wright, A., Wright, D., Nicolaides, K.H., Uterine artery pulsatility index in the three trimesters of pregnancy: effects of maternal characteristics and medical history. Ultrasound Obstet Gynecol 45 (2015), 689–697.
17. Wright, D., Silva, M., Papadopoulos, S., Wright, A., Nicolaides, K.H., Serum pregnancy associated plasma protein-A in the three trimesters of pregnancy: effects of maternal characteristics and medical history. Ultrasound Obstet Gynecol 46 (2015), 42–50.
18. Tsiakkas, A., Duvdevani, N., Wright, A., Wright, D., Nicolaides, K.H., Serum placental growth factor in the three trimesters of pregnancy: effects of maternal characteristics and medical history. Ultrasound Obstet Gynecol 45 (2015), 591–598.
19. Robinson, H.P., Fleming, J.E., A critical evaluation of sonar crown rump length measurements. Br J Obstet Gynaecol 82 (1975), 702–710.
20. Brown, M.A., Lindheimer, M.D., de Swiet, M., Van Assche, A., Moutquin, J.M., The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 20 (2001), IX–XIV.
21. R Development Core Team. R: a language and environment for statistical computing. 2011, R Foundation for Statistical Computing, Vienna (Austria).
22. Navaratnam, K., Alfirevic, A., Alfirevic, Z., Low dose aspirin and pregnancy: how important is aspirin resistance?. BJOG 123 (2016), 1481–1487.
23. Breckenridge, A., Aronson, J.K., Blaschke, T.F., Hartman, D., Peck, C.C., Vrijens, B., Poor medication adherence in clinical trials: consequences and solutions. Nat Rev Drug Discov 16 (2017), 149–150.